Blocking the PD‐1 receptor, preventing binding and activation of PD‐L1 and PD‐L2; the inhibition of the PD‐1 pathway results in immune checkpoint enhancing T‐cell‐mediated immune response leading to T‐cell activation and proliferation against tumor cells. This evidence concerns the gene PDCD1 and neoplasm.